XML 35 R22.htm IDEA: XBRL DOCUMENT
v3.8.0.1

Revenues (Tables) | 3 Months Ended
--- | ---
Mar. 30, 2018
Revenue from Contract with Customer [Abstract] |
Disaggregation of Revenues | Total revenues disaggregated by significant customer were as follows (dollars in thousands):
| Three Months Ended March 31,
| 2018 |  | 2017
| Dollars |  | Percent of total |  | Dollars |  | Percent of total
Ipsen | $ | 53,809 |  |  | 25 | % |  | $ | 4,530 |  |  | 6 | %
Caremark L.L.C. | $ | 26,388 |  |  | 12 | % |  | $ | 13,819 |  |  | 17 | %
Affiliates of McKesson Corporation | $ | 21,331 |  |  | 10 | % |  | $ | 11,278 |  |  | 14 | %
Diplomat Specialty Pharmacy | $ | 20,147 |  |  | 9 | % |  | $ | 19,850 |  |  | 25 | %
Accredo Health, Incorporated | $ | 18,286 |  |  | 9 | % |  | $ | 9,440 |  |  | 12 | %
Revenues by disaggregated category were as follows (in thousands):
| Three Months Ended March 31,
| 2018 |  | 2017
Product revenues: |  |  |
Gross product revenues | $ | 159,436 |  |  | $ | 77,959 |
Discounts and allowances | (25,164 | ) |  | (9,082 | )
Net product revenues | 134,272 |  |  | 68,877 |
Collaboration revenues: |  |  |
License revenues (1) | 69,030 |  |  | 11,214 |
Research and development services revenues (2) | 10,099 |  |  | 1,132 |
Product supply revenues, net | (1,055 | ) |  | (336 | )
Total collaboration revenues | 78,074 |  |  | 12,010 |
Total revenues | $ | 212,346 |  |  | $ | 80,887 |
____________________
(1) | License revenues for the three months ended March 31, 2018 included revenues related to the portion of two milestones that were allocated to the transfer of intellectual property licenses and were fully recognized in the current period and royalty revenue from Ipsen and Genentech. License revenues for the three months ended March 31, 2017 included the recognition of deferred revenues from upfront payments and a non-substantive milestone that were being amortized over various periods, royalty revenues from Ipsen and Genentech and one milestone. Upon the adoption of Topic 606, the allocation of proceeds from our collaboration partners between licenses and research and development services as well as the timing of recognition has changed. Therefore, among other changes, as of January 1, 2018, the portion of proceeds allocated to intellectual property licenses for our Ipsen and Takeda collaboration agreements are recognized immediately and license revenues no longer includes revenues related to the amortization of deferred revenue.
(2) | Research and development services revenues for three months ended March 31, 2018 included the recognition of deferred revenue for the portion of the upfront payments and milestones that were allocated to the research and development services which are being amortized through early 2030, as well as development cost reimbursements earned on our collaboration agreements. As described above, we did not allocate any of our upfront payments or milestones to research and development services prior to the adoption of Topic 606 and therefore research and development services revenues for the three months ended March 31, 2017 included only development cost reimbursements earned on our collaboration agreements.
Net product revenues disaggregated by product were as follows (in thousands):
| Three Months Ended March 31,
| 2018 |  | 2017
CABOMETYX | $ | 128,934 |  |  | $ | 62,359 |
COMETRIQ | 5,338 |  |  | 6,518 |
Net product revenues | $ | 134,272 |  |  | $ | 68,877 |
Total revenues disaggregated by geographic region were as follows (in thousands):
| Three Months Ended March 31,
| 2018 |  | 2017
U.S. | $ | 135,620 |  |  | $ | 73,675 |
Europe | $ | 53,809 |  |  | $ | 4,530 |
Rest of the world | $ | 22,917 |  |  | $ | 2,682 |
Activities and Ending Reserve Balances for Significant Categories of Discounts and Allowances | The activities and ending reserve balances for each significant category of discounts and allowances (which constitute variable consideration) were as follows (in thousands):
| Chargebacks and Discounts for Prompt Payment |  | Other Customer Credits/Fees and Co-pay Assistance |  | Rebates |  | Returns |  | Total
Balance at December 31, 2017 | $ | 1,928 |  |  | $ | 1,795 |  |  | $ | 5,770 |  |  | $ | — |  |  | $ | 9,493 |
Provision related to sales made in: |  |  |  |  |  |  |  |  |
Current period | 14,475 |  |  | 4,197 |  |  | 6,625 |  |  | — |  |  | 25,297 |
Prior periods | (331 | ) |  | — |  |  | 199 |  |  | — |  |  | (132 | )
Payments and customer credits issued | (13,556 | ) |  | (3,294 | ) |  | (3,303 | ) |  | — |  |  | (20,153 | )
Balance at March 31, 2018 | $ | 2,516 |  |  | $ | 2,698 |  |  | $ | 9,291 |  |  | $ | — |  |  | $ | 14,505 |
Contract Assets and Liabilities under Topic 606 | Changes in our contract assets and liabilities under Topic 606 were as follows (in thousands):
| Contract Assets: Unbilled Collaboration Revenue |  | Contract Liabilities: Deferred Revenue
| Current Portion |  | Long-term Portion |  | Current Portion |  | Long-term Portion
Balance at December 31, 2017 | $ | — |  |  | $ | — |  |  | $ | 31,984 |  |  | $ | 238,520 |
Adoption of Topic 606 | 9,588 |  |  | 12,247 |  |  | (23,591 | ) |  | (213,079 | )
Balance at January 1, 2018 | 9,588 |  |  | 12,247 |  |  | 8,393 |  |  | 25,441 |
Increases as a result of a change in transaction price and recognition of revenues as services are performed | 46,006 |  |  | 1,166 |  |  | — |  |  | — |
Transfer to receivables from contract assets recognized at the beginning of the period | (9,159 | ) |  | — |  |  | — |  |  | — |
Increases as a result of the deferral of milestones earned in period, excluding amounts recognized as revenue | — |  |  | — |  |  | 173 |  |  | 666 |
Revenue recognized that was included in the contract liability balance at the beginning of the period | — |  |  | — |  |  | (3,492 | ) |  | — |
Other adjustments (1) | (14,591 | ) |  | (13,413 | ) |  | (5,074 | ) |  | (22,930 | )
Balance at March 31, 2018 | $ | 31,844 |  |  | $ | — |  |  | $ | — |  |  | $ | 3,177 |
____________________
(1) | Includes reclassification of deferred revenue from long-term to current and adjustments made due to netting of contract assets and liabilities by collaboration agreement.

X
- Definition Reconciliation Of Sales Discount And Allowances Reserve Balances [Table Text Block] + References No definition available. + Details
Name: | exel_ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock
Namespace Prefix: | exel_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of contract balances and changes in contract balances. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 10 -URI http://asc.fasb.org/extlink&oid=82913847&loc=SL49130551-203045 + Details
Name: | us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 5 -URI http://asc.fasb.org/extlink&oid=82913847&loc=SL49130545-203045 + Details
Name: | us-gaap_DisaggregationOfRevenueTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_RevenueFromContractWithCustomerAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration